It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.

If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force [1]. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.

- read the report [2] from Fortune

Related Articles:
Pfizer-Sanofi match not made in heaven? Report [2]
Sanofi stock up on Pfizer buyout talk. Report [2]
Pfizer, Wyeth merger bad idea? Report [2]

Read more on: Pfizer [3] | Sanofi-Aventis [4]